Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand - PubMed (original) (raw)

. 2004 Mar 15;189(6):990-1000.

doi: 10.1086/382280. Epub 2004 Mar 1.

Affiliations

• PMID: 14999601
• DOI: 10.1086/382280

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

Timothy P Endy et al. J Infect Dis. 2004.

Abstract

Background: Infection with any 1 of the 4 dengue viruses (DVs) can produce several illnesses, ranging from a mild febrile illness to classic dengue fever (DF) to dengue hemorrhagic fever (DHF), a potentially life-threatening disease. Most DHF cases occur after sequential heterotypic DV infections. The role of preexisting humoral immunity in modifying severity of dengue disease is not well understood.

Methods: We conducted a prospective cohort study of children in a region where dengue disease is hyperendemic and examined the role of preexisting neutralizing anti-DV antibodies (Abs) in modifying secondary dengue-3 virus (D3V), dengue-2 virus (D2V), and dengue-1 virus (D1V) infections.

Results: In secondary D3V infection, higher levels of preexisting neutralizing Ab directed against D3V (reference virus strain and patient's virus isolate) were associated with lower viremia levels and milder disease. Preexisting neutralizing Ab levels against D2V were not associated with severity of secondary D2V infection. The levels of preexisting neutralizing Ab against the infecting virus isolates were not associated with viremia levels in secondary D2V or D1V infections.

Conclusions: Cross-reactive memory humoral immune responses appear to be beneficial in symptomatic secondary D3V infection, but not in secondary D2V or D1V infection. These results may have important implications for the development of live attenuated tetravalent dengue vaccines.

PubMed Disclaimer

Similar articles

• Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.
  Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Reed G, Ennis FA, Rothman AL, Green S. Laoprasopwattana K, et al. J Infect Dis. 2005 Aug 1;192(3):510-9. doi: 10.1086/431520. Epub 2005 Jul 5. J Infect Dis. 2005. PMID: 15995967
• Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.
  Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. Vaughn DW, et al. J Infect Dis. 2000 Jan;181(1):2-9. doi: 10.1086/315215. J Infect Dis. 2000. PMID: 10608744
• Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response.
  Guilarde AO, Turchi MD, Siqueira JB Jr, Feres VC, Rocha B, Levi JE, Souza VA, Boas LS, Pannuti CS, Martelli CM. Guilarde AO, et al. J Infect Dis. 2008 Mar 15;197(6):817-24. doi: 10.1086/528805. J Infect Dis. 2008. PMID: 18269315
• Innate immune responses to dengue virus.
  Navarro-Sánchez E, Desprès P, Cedillo-Barrón L. Navarro-Sánchez E, et al. Arch Med Res. 2005 Sep-Oct;36(5):425-35. doi: 10.1016/j.arcmed.2005.04.007. Arch Med Res. 2005. PMID: 16099317 Review.
• Immunity and immunopathology in dengue virus infections.
  Kurane I, Ennis FE. Kurane I, et al. Semin Immunol. 1992 Apr;4(2):121-7. Semin Immunol. 1992. PMID: 1617166 Review.

Cited by

• Why do adaptive immune responses cross-react?
  Fairlie-Clarke KJ, Shuker DM, Graham AL. Fairlie-Clarke KJ, et al. Evol Appl. 2009 Feb;2(1):122-31. doi: 10.1111/j.1752-4571.2008.00052.x. Epub 2008 Dec 8. Evol Appl. 2009. PMID: 25567852 Free PMC article.
• Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.
  Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, de Silva AM, Baric RS. Messer WB, et al. PLoS Negl Trop Dis. 2012;6(2):e1486. doi: 10.1371/journal.pntd.0001486. Epub 2012 Feb 28. PLoS Negl Trop Dis. 2012. PMID: 22389731 Free PMC article.
• Virus-specific differences in rates of disease during the 2010 Dengue epidemic in Puerto Rico.
  Sharp TM, Hunsperger E, Santiago GA, Muñoz-Jordan JL, Santiago LM, Rivera A, Rodríguez-Acosta RL, Gonzalez Feliciano L, Margolis HS, Tomashek KM. Sharp TM, et al. PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2159. doi: 10.1371/journal.pntd.0002159. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23593526 Free PMC article.
• HLA-B∗44 Is Associated with Dengue Severity Caused by DENV-3 in a Brazilian Population.
  Xavier Eurico de Alencar L, de Mendonça Braga-Neto U, José Moura do Nascimento E, Tenório Cordeiro M, Maria Silva A, Alexandre Antunes de Brito C, da Silva Mda P, Gil LH, Montenegro SM, Marques ET Jr. Xavier Eurico de Alencar L, et al. J Trop Med. 2013;2013:648475. doi: 10.1155/2013/648475. Epub 2013 Jun 2. J Trop Med. 2013. PMID: 23818909 Free PMC article.
• Dengue: A Minireview.
  Harapan H, Michie A, Sasmono RT, Imrie A. Harapan H, et al. Viruses. 2020 Jul 30;12(8):829. doi: 10.3390/v12080829. Viruses. 2020. PMID: 32751561 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal